Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

• Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
• Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
• Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
• Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
• Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
• Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
• Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

• Introduction (00:00)
• Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
• Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
• Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
• Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
• Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:

• Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)
• Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)
• Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)

CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction: ODAC — April 30, 2026 (00:00)
• Adjuvant CDK4/6 Inhibitors (13:03)
• Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
• Premenopausal Patients (30:52)
• Duration of Adjuvant Endocrine Treatment (38:44)
• Genomic Predictors of Chemotherapy Benefit (47:19)
• Neoadjuvant Treatment (55:13)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)
• Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)

CME information and select publications

Featuring an interview with Dr Jamie E Chaft, including the following topics:

• Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)
• Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)
• Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)
• Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)
• Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)
• Importance of clinical trials in the adjuvant setting (33:02)
• Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)
• Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)
• Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
• Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

• Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
• Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
• Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
• Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information an d select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:

• Introduction (00:00)
• Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
• Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
• Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
• Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
• Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Featuring an interview with Dr Floor J Backes, including the following topics:

• Overview of the treatment landscape of endometrial cancer (00:00)
• Immunotherapy for advanced endometrial cancer (03:58)
• Contraindications for immunotherapy (18:15)
• PARP inhibitors for endometrial cancer (20:12)
• Management of localized endometrial cancer (28:23)
• Novel strategies under investigation for endometrial cancer (42:27)

CME information and select publications